Seres Therapeutics Makes Significant Progress with SER-155
Recently, Seres Therapeutics has received valuable feedback from regulatory authorities, which is paving the way for the completion of its important SER-155 Phase 2 study protocol. This study focuses on preventing bloodstream infections in adults who are undergoing allogeneic hematopoietic stem cell transplant for hematological malignancies. The positive interaction with the FDA indicates a step closer to initiating clinical operations.
Engagements for Capital and Future Directions
The company is actively engaging with several stakeholders to secure capital and additional resources necessary for advancing the SER-155 Phase 2 study. There is a strong emphasis on preparing to operationalize the study as soon as financing is secured, with interim clinical results expected as early as 12 months after the study begins.
Cost-Reduction Strategy for Sustainable Growth
In an effort to streamline operations and ensure sustainability, Seres Therapeutics has announced plans to reduce its workforce by approximately 25%. These strategic cost-cutting measures are designed to extend the company’s financial runway, potentially into the second quarter of 2026. The anticipated savings from these changes are expected to offer Seres the needed flexibility to focus on its primary objectives.
Focus on SER-155 and Clinical Studies
The SER-155 Phase 2 study is designed to be robust, involving a placebo-controlled format that will track the prevention of bloodstream infections for up to 30 days post-allogeneic hematopoietic stem cell transplant. With a planned enrollment of around 248 participants, the interim analysis will help facilitate discussions with the FDA regarding a Phase 3 study, enhancing the clinical development pathways for this promising live biotherapeutic.
Understanding SER-155 and Its Importance
SER-155 aims to decolonize harmful gastrointestinal pathogens and bolster the immune system to protect patients undergoing allo-HSCT from severe infections that could lead to increased morbidity and associated complications. Previous studies have shown that SER-155 may significantly reduce both the incidence of infections and the need for systemic antibiotics in patients.
The Journey of Seres Therapeutics
Seres Therapeutics is well-recognized for pioneering novel live biotherapeutics aimed at treating vulnerable patient populations. Its prior achievement, the FDA-approved VOWST™, showcases the company’s commitment to innovative therapeutic solutions. With the ongoing development of SER-155, Seres intends to address numerous pathways relevant to infectious diseases while maintaining an adaptable operating model to support long-term growth.
Frequently Asked Questions
What is SER-155 designed to do?
SER-155 is an investigational live biotherapeutic aimed at preventing bloodstream infections in patients undergoing allo-HSCT by improving gut health and immune function.
What changes has Seres Therapeutics implemented recently?
Seres has announced a 25% workforce reduction and is implementing cost-saving measures to extend its operational runway into 2026.
How does the FDA feedback affect the SER-155 study?
The FDA's constructive feedback is instrumental in finalizing the SER-155 Phase 2 study protocol, enhancing its design and execution.
What are the expected outcomes of the SER-155 Phase 2 study?
The study aims to demonstrate the efficacy of SER-155 in reducing bloodstream infections, with interim results anticipated within 12 months post initiation.
What role does investor engagement play in Seres' strategy?
Engaging investors is critical for Seres as it seeks to secure capital to fund the SER-155 study and support its broader therapeutic pipeline.
